The 2016 revised World Health Organization (WHO) classification includes several provisional borderline categories for lymphoma cases that do not clearly fit into one entity, such as B-cell lymphoma, unclassifiable (BCLU), with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). This CARD focuses on lymphomas that are intermediate between DLBCL of the primary mediastinal large Bcell lymphoma (PMLBCL) type and cHL
Clinics and pathology

Disease
Most lymphomas are considered to represent distinct disease entities since they have characteristic immunophenotypic profiles and recurrent genetic abnormalities, and can accordingly be diagnosed using available techniques. However, the 2016 revised WHO classification has introduced new provisional borderline ("grey zone") categories for cases that do not clearly fit into one entity. This includes a category termed B-cell lymphoma, unclassifiable (BCLU) (Figure 1 ).This CARD focuses specifically on the category of B-cell lymphoma that is intermediate between DLBCL of the primary mediastinal large B-cell lymphoma (PMLBCL) type and cHL , Carbone et al., 2010 Swerdlow et al., 2016) . H&E stain, magnification x60. 
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma
Other features
Immunophenotype See table2.
Genetics
Specific genetic changes characteristic of BCLU with features intermediate between PMLBCL and cHL have not been definitively shown. Like DLBCL (NOS) and PMLBCL, these lymphomas may demonstrate deregulation of B-cell signaling or transcriptional regulation and apoptosis (e.g. BCL6 gene rearrangement, activation of NFKB pathway, constitutive activation of STAT6) (Carbone et al., 2010; Swerdlow et al., 2016; Carbone and Gloghini 2016) . However, unlike cHL Epstein-Barr virus sequences have been found in fewer (20% or less) cases.
